Kissei Pharmaceutical Co., Ltd is conducting a study to evaluate the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic ITP under actual conditions of use. The study is open to all age groups receiving fostamatinib for the first time.
Japan
Actively Recruiting